高血压患者血清脂联素水平与血管重构的相关性研究
|
摘要
目的：
研究高血压患者血清脂联素水平与颈动脉内膜中层厚度、踝臂指数的相关性。
方法：
依照中国高血压防治指南(2005年修订版)制定的诊断标准,将入选者分为正常对照组(40例)和高血压组(120例)。高血压组按不同血压水平分为3个亚组：1级高血压组、2级高血压组、3级高血压组。所有入选者均检测血压、身高、体重、腰围、臀围等指标,计算体质量指数(BMI)、胰岛素抵抗指数(HOMA-IR)等。采用酶联免疫吸附法测定血清脂联素浓度。应用美国ATL彩色多普勒超声仪检测颈动脉内膜中层厚度。应用日本ES—100V3超声仪测量并计算受试者踝臂指数。
结果：
(1)与正常对照组比较,高血压组血清脂联素浓度、踝臂指数明显降低,颈动脉内膜中层厚度增加,差异具有统计学意义(P＜0.05)。且高血压各亚组间两两比较也具有统计学差异,说明脂联素浓度随着血压升高逐渐降低,而颈动脉内膜中层厚度呈逐渐增高趋势。2级、3级高血压组与正常组比较,踝臂指数差异具有统计学意义(P＜0.05)。高血压各亚组间两两比较踝臂指数差异无统计学意义(P＞0.05)。(2)Pearson相关分析显示,高血压组脂联素浓度与收缩压、舒张压、BMI、TG、HO MA-IR.颈动脉内膜中层厚度呈负相关(P＜0.05,P＜0.01),与踝臂指数呈正相关(P＜0.05),而与PP、TC、HDL-C、LDL-C相关性不显著。(3)多元线性回归分析显示,高血压组年龄、收缩压、BMI、TG是影响血清脂联素的独立因素(R2=0.580,P＜0.05)。
结论：
血清脂联素浓度与颈动脉内膜中层厚度、踝臂指数密切相关。脂联素可能是高血压患者发生早期血管病变的中介环节,可作为预测血管病变程度的指标,并有可能成为今后高血压患者治疗的靶点之一。
Obesity:To evaluate the relationship between the adiponectin (APN) levels and intima-media thickness (IMT)、ankle brachia index (ABI) in patients with essential hypertension(EP).
Methods:120 patients with essential hypertension and 40 healthy subjects were studied.Then we divided the EP group to 3 subgroups according to the blood pressure levels.Serum adiponectin was assayed by radio-immunoassay (RIA), and related parameters such as blood pressure、height、weight、waist circumference (WC) and so on were measured. According to the typical HOMA model, insulin resistance index (HOMA-IR) were calculated.Intima-media thickness and ankle brachia index were both determined.
Results:(1)Compared with the healthy group, the serum APN、ABIof the EP group was lower and the IMT was higher (P<0.05). The differences of serum APN、IMT between healthy group、1、2、3 subgroups were both significant. (2) Pearson-correlation analysis revealed APN of EP group was negatively correlated with SBP、DBP、BMI、TG、HOMA-IR、IMT(P<0.05, P (0.01). APN was positive correlation with ABI(P <0.05). (3) Multiple regression analysis showed that age、SBP、BMI、TG were independent factor to logAPN in EP group (R2=0.580, P<0.05).
Conclusion:The serum adiponectin has a closed relationship with intima-media thickness and ankle brachia index. Adiponectin maybe joined in the process of hypertension. It suggests that APN could be the index to vascular remodeling of hypertension. And APN could be used in the therapy of the hypertension.
研究高血压患者血清脂联素水平与颈动脉内膜中层厚度、踝臂指数的相关性。
方法：
依照中国高血压防治指南(2005年修订版)制定的诊断标准,将入选者分为正常对照组(40例)和高血压组(120例)。高血压组按不同血压水平分为3个亚组：1级高血压组、2级高血压组、3级高血压组。所有入选者均检测血压、身高、体重、腰围、臀围等指标,计算体质量指数(BMI)、胰岛素抵抗指数(HOMA-IR)等。采用酶联免疫吸附法测定血清脂联素浓度。应用美国ATL彩色多普勒超声仪检测颈动脉内膜中层厚度。应用日本ES—100V3超声仪测量并计算受试者踝臂指数。
结果：
(1)与正常对照组比较,高血压组血清脂联素浓度、踝臂指数明显降低,颈动脉内膜中层厚度增加,差异具有统计学意义(P＜0.05)。且高血压各亚组间两两比较也具有统计学差异,说明脂联素浓度随着血压升高逐渐降低,而颈动脉内膜中层厚度呈逐渐增高趋势。2级、3级高血压组与正常组比较,踝臂指数差异具有统计学意义(P＜0.05)。高血压各亚组间两两比较踝臂指数差异无统计学意义(P＞0.05)。(2)Pearson相关分析显示,高血压组脂联素浓度与收缩压、舒张压、BMI、TG、HO MA-IR.颈动脉内膜中层厚度呈负相关(P＜0.05,P＜0.01),与踝臂指数呈正相关(P＜0.05),而与PP、TC、HDL-C、LDL-C相关性不显著。(3)多元线性回归分析显示,高血压组年龄、收缩压、BMI、TG是影响血清脂联素的独立因素(R2=0.580,P＜0.05)。
结论：
血清脂联素浓度与颈动脉内膜中层厚度、踝臂指数密切相关。脂联素可能是高血压患者发生早期血管病变的中介环节,可作为预测血管病变程度的指标,并有可能成为今后高血压患者治疗的靶点之一。
Obesity:To evaluate the relationship between the adiponectin (APN) levels and intima-media thickness (IMT)、ankle brachia index (ABI) in patients with essential hypertension(EP).
Methods:120 patients with essential hypertension and 40 healthy subjects were studied.Then we divided the EP group to 3 subgroups according to the blood pressure levels.Serum adiponectin was assayed by radio-immunoassay (RIA), and related parameters such as blood pressure、height、weight、waist circumference (WC) and so on were measured. According to the typical HOMA model, insulin resistance index (HOMA-IR) were calculated.Intima-media thickness and ankle brachia index were both determined.
Results:(1)Compared with the healthy group, the serum APN、ABIof the EP group was lower and the IMT was higher (P<0.05). The differences of serum APN、IMT between healthy group、1、2、3 subgroups were both significant. (2) Pearson-correlation analysis revealed APN of EP group was negatively correlated with SBP、DBP、BMI、TG、HOMA-IR、IMT(P<0.05, P (0.01). APN was positive correlation with ABI(P <0.05). (3) Multiple regression analysis showed that age、SBP、BMI、TG were independent factor to logAPN in EP group (R2=0.580, P<0.05).
Conclusion:The serum adiponectin has a closed relationship with intima-media thickness and ankle brachia index. Adiponectin maybe joined in the process of hypertension. It suggests that APN could be the index to vascular remodeling of hypertension. And APN could be used in the therapy of the hypertension.
引文
[1]中国高血压防治指南.高血压杂志,2005,13(增刊)：2-42
[2]翁心植等译.心肺血管报,1984,2(1)：21
[3]陈宏.高血压血管重构及高血压状态下的颈动脉血管重构.中国组织工程研究与临床康复,2007,2(14)：2724-2729
[4]孙宁玲.血管弹性功能应作为高血压亚临床损害评估的一个重要靶点.中国循环杂志,2008,23(3)：161-163
[5]张维忠.早期发现和检测亚临床血管病变.中华新血管病杂志,2007,35(10)：881-882
[6]Dzau VJ.Antman EM.Black HR, et al. The cardiovascular disease continuum validated :clinical eviden-ce of improved patient outcomes: Pathop-hysiology and clinical trial evidence.Circulation,2006,(114): 2850-2870
[7]CleemJL. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel detection, evaluation, and treatment of high blood cholesterol in adults(adult treatment panelⅢ).JAMA,2001,285(19):2486-2497
[8]Scherer PE. Adipose tissue:from lipid storage compartment to endocrine organ. Diabetes.2006,55 (3): 1537-1545
[9]Adamczak M. Wiecek A. Funahashi T, et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens,2003,16(2):72-75
[10]Yang WS.Lee WJ.Funahashi T,et al.Plasma adipnectin levels in overweight and obese Asians.Obes Res,2002,10(11):1104-1110
[11]Paolo Calabro. Enrica Golia,et al.CRP and the risk of atherosclerotic events. Semin Immunopathol 2009,4 (31):79-94
[12]胡大一.重视踝臂指数,关注下肢外周动脉疾病.中国医药导刊,2005,7(1)：29-31
[13]Greenland P. Abrams J. Aurigemma GP, et al.Prevention Conference V:beyond secondary prevention: identifying the high risk patient for primary prevention:noninvasive tests of atherosclerotic burden: Writing Group.Circulation,2000,101 (1):16-22
[14]Scherer PE. Willians S. Fogliano M, et al. A novel serum protein similar to Cl q, produced exclusively in adipocytes. BioChem,1995,270(10):26746-26749
[15]Nakano Y. Tobe T. Choi-Miura NH, et al. Isolation and characterization of GBP28.a novel gelatin bi-nding protein purified from human plasma. BioChem (Tokyo),1996,120(3):803-812
[16]Arita Y.Kihara S.Ouchi N,et a 1.Paradoxical decrease of an adipose-specific protein, adiponectin in obe-sity. Biochem Biophys Res Commun,1999,257(10):79-83
[17]Tsioufis C. Dimitriadis K. Antoniadid D, et al.Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Hypertens,2004, 17:470-476
[18]Schulze M. Rimm E. Shai I, et al.Relationships of between adiponectin and glycemic control, blood lipi-ds,and inflammatory makers in men with type 2 diabetes. Diabetes Care,2004,27:1680-1687
[19]毋淑珍,赵洛沙,杨文等.原发性高血压患者血清脂联素水平及与血压、胰岛素抵抗的关系.中国心血管病研究杂志,2007,6(5)：414-416
[20]Mallamaci F. Zoccali C. Culola F, et al.Adiponectin in essential hypertension.Nephrol,2002,15:507-511
[21]Wing-Sun Chow. Bernard M.Y. Cheung. Annette W.K, et al. Hypoadiponectinemia as a Predictor for the development of Hypertension,A 5-Year Prospective Study. Am j Hypertens,2007,49:1455-1461
[22]Costas Tsioufis.Kyriakos Dimitriadis.Dmitris Chatzis, et al.Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Circulation,2005,5 (5):94 6-951
[23]李新立,童敏,徐琼等.平均动脉压水平与血清脂联素浓度的相关性研究.中华心血管病杂志,2007,35(4)：320-324
[24]Zoico E.Di Francesco V.Mazzali C, et al.Adipocytokines,for distribution, and insulin resistance in eldely men an women.Gerontol A Bio Sci,2004,59(9):935-939
[25]J.S.Nam, J.S.Park, M.H.Cho, et al.The association between pulse wave velocity and metabolic syndrome and adiponectin in patients with impaired fasting glucose:cardiovascular risks and adiponectin in IFG. Diabetes research and clinical practice.2009,84(3):145-151
[26]周淑娴,雷娟,张玉玲等.高血压患者胰岛素抵抗与血清脂联素及炎症标志物水平.中华高血压杂志,2008,16(2)：166-170
[27]Anna Maria Sironi. Alessandro Pingitore. Sergio Ghione, et al. Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Am j Hypertens,2008, 51(3):282-288
[28]常彩云.血清脂联素水平与胰岛素抵抗、高血压的相关性研究：[硕士学位论文].山东：山东大学,2007
[29]Yoshio Iwashima, Tomohiro Katsuya, Kazuhiko Ishikawa, et al. Hypoadiponectinemia is an independ-ent risk factor for hypertension. Am j Hypertens,43(6):1318-1323
[30]Fasshauer M.Klein J. Neumann S, et al.Adiponectin gene expression is inhibited by beta-adrenergic sti-mulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett.,2001,507(3):142-146.
[31]Sharma AM.Janke J.Gorzelniak K,et al. Angiotensin bloekade prevents type2 diabetes by formation of fat cells.Hyertension,2002,40(5):609-611
[32]FasshauerM,KleinJ,NeumannS, et al. Adiponectin gene expression 15inhibited By beta-adrenergic stimulation via ProteinkinaseAin3T3-LladiPocytes.FEBS Lett,2001,507(2):142-146
[33]Kondo H.Shimomura I.Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes:a candidate gene for the insulin resistance syndrome. Diabetes.2002,51(8):2325-2328.
[34]Iwashima Y.Katsuya T. Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hyper- tension. Hypertension,2004,43(4):1318-1323
[35]Joseph T. What is the significance of increased carotid intima media thickness in hypertensive adolesce-nts? Hypertension,2006,48(5):23-24
[36]Litwin M.Trelewicz J. Wawer Z et al. Intima-media thickness and arterial elasticity in hypertensive ch-ildren:controlled study. Pediatr Nephrol,2004,19(1):161-114
[37]Tzou WS. Douglas PS. Srinivasan SR, et al.Increased subclinical atherosclerosis in young adults with metabolic syndrome. The Bogalusa Heart Study. J Am Coll Cardiol.2005,46:457-463
[38]Mattace-Raso F.van der Cammen T. Hofman A, et al. Arterial stiffness and risk of coronary heart dise-ase and stroke; The Rotterdam Study. Circulation,2006,113(4):657-663
[39]Ouchi N.Kihara S.Arita Y,et al.Adipocyte—derived plasma protein, adiponectin, suppresses lipid ac-cumulation and class A scavenger receptor expression in human monocyte—derived macmphages.Circ-ulation,2001,103(8):1057-1060
[40]Altinova AE. Toruner F.Bukan N, et al. Decreased plasma adiponectin is associated with insulin resista-nce and HDL cholesterol in overweight subjects. Endocr J 2007,54(5):221-226
[41]Sasaki R.Yamano S, et al. Vascular remodeling of the carotid artery in patient with untreated essential hypertension increases with age. Hypertens Res,2002,25(3):373-379
[42]Nilsson PM. Engstrom G. Hedblad B,et al. Plasma adiponectin levels in relation to carotid intima-media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol.2006,26(9):2758-2762
[43]张竹林.脂联素、血管内皮功能与代谢综合征相关性研究：[硕士学位论文].山西：山西医科大学,2007
[44]T. Hansena. A.hlstrom a, et al. Visceral adipose tissue, adiponectin levels and insulin resistance are rela-ted to atherosclerosis as assessed by whole-body magnetic resonance angiography in an elderly populat-ion.Atherosclerosis,2008,11(7):1016-1023
[45]Pilar Arnaiz. Monica Acevedo b.Salesa Barja, et al. Adiponectin levels, cardiometabolic risk factors and markers of subclinical atherosclerosis in children. Circulation,2008,8 (7):217-224
[46]Safar ME. Pulse pressure in essential hypertension:clinical and therapeutical implication. Hypertension,1989,7(5):769-776
[47]张维忠.早期发现和检测亚临床血管病变.中华心血管病杂志,2007,35(10)：881-882
[48]孙宁玲.血管弹性功能应作为高血压亚临床损害评估的一个重要靶点.中国循环杂志,2008,23(3)：161-163
[49]Kobayashi K.Akishita M.Yu W, et al.Interrelationship between no-invasive measurements of atherosc-lerosis:flow-mediated dilation of branchial artery,carotid intima-media thickness and pulse wave veloc-Ity. Atherosclerosis,2004,173(5):13-18
[50]Sikkink CJ.van Asten WN. vant Hof MA,et al. Decreased ankle/brachial index in relation to morbidi-ty and mortality in patients with peripheral arterial disease. Vasc Med,1997,2(9):169-173
[51]Hirsch AT. Haskal ZJ. Hertzer NR,等著.杨金刚.王建旗.李觉.等编译.外周动脉疾病诊疗指南[M]上海,同济大学出版社,2006,2(17)：42-45
[52]杨静.李新立.黄峻等.高血压患者血清抵抗素水平与大动脉弹性的关系.中华心血管病杂志,2009,37(3)：244-247
[53]何大渊.余静等.高血压病患者血浆Apelin-12和踝臂指数的相关影响因素.中华临床医学实践杂志,2006,12(5)：497-500
[54]Nguyen QM. Srinivasan SR. Xu JH, et al. Racial (black-white) divergence in the association between adi-ponectin and arterial stiffness in asymptomatic young adults:the Bogalusa heart study. Hypertens, 2008,21(5):553-557
[55]刘伯芹.血浆脂联素水平与冠脉病变及PWI、 ABI的关系研究：[硕士学位论文].青岛：青岛医科大学,2009
[56]Kunihiho koshiba. Efficacy glimepiride on insulin resistance, adipocytokines, and atherosclerosis. The journal of medical investigation,2006,2(53):87-94
[1]Scherer PE.Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes.2006,55(3): 1537-1545
[2]Kadowaki T.Yamauchi T.Kubota N,et al. Adiponectin and adiponectin receptors in insulin resistance, di abetes, and the metabolic syndrome. J Clin Invest.2006,116(6):1784-1792
[3]Kearney PM.Whelton M.Reynolds K,et al.Global burden of hypertension: analysis of worldwide data. L ancet.2005,365(9):217-223
[4]Funahashi T.Shimomura I.Adiponectin replenishment ameliorates obesity-related hypertension. Hyperte-nsion.2006,47(7):1108-1116
[5]Iwashima Y.Katsuya T.Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hyperte-nsion.Hypertension.2004,43(2):1318-1323
[6]Scherer PE.Willians S.Fogliano M, et al.A novel serum protein similar to Clq, produced exclusively in adipocytes.J Biol Chem,1995,270(5):2646-2649
[7]Maeda K, Okubo K, Shimomura I, et al.cDNA cloning and expression of a novel adipose specific colla-gen like factor apM1(adipose most abundant gene transcript).Biochem Biophys Res Commun,1996, 221(8):286-289
[8]Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin bind-ing protein purified from human plasma J Biochem (Tokyo),1996,120(3):803-812
[9]Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.Biochem Biophys Res Commun,1999,257(6):79-83
[10]Ohashi K. Ouchi N.Kihara S,et al.Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease.J Am Coil Cardiol.2004,43(7):1195-1200
[11]Stumvoll M.Tshritter O.Frissche A, et al.Association of the T-Gpilymorphism in adiponectin with obesit and insulin sensitivity,interaction with family history of type 2 diabetes,2002,51(1):37-41
[12]Sattar N.Watt P.Cherry L, et al.High molecular weight adiponectin is not associated with incident coron-ary heart disease in older women:a nested prospective case control study. J Clin Endocrinol Metab 2008,93(5):1846-1849
[13]Pajvani UB.Hawkins M.Combs TP, et al. Complex distribution, not absolute amount of adiponectin,corr-elates with thiazolidinedionemediated improvement in insulin sensitivity. J Biol Chem.2004,279(7):121-52-12162
[14]Tonelli J.Li W.Kishore P, et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.Diabetes.2004,53(10):1621-1629
[15]Lara-Castro C.Luo N.Wallace P, et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster.Diabetes.2006,55(5):249-259
[16]Kondo H.Shimomura L.Maukawa Y,et al.Association of adipo nectin mutation with type 2 diabetes:a ca-ndidate gene for the insulin resistance syndrome.Diabetes,2002,51(7):2325-2328
[17]Bacha F.Saad R.Gungor N, et al.Does adiponectin explmn the lower insulin sensitivity and hyperinsulin-emia of African-American children. Diabetes,2005,6(2):100-102
[18]Maeda N.Takab ashi M.Funab ashi T,et al.PPARgamma ligands increase expression and plasma concen-trateons of adiponectin,an adipose—derived protein.Diabetes,2001,50(9):2094-2099
[19]Chujo D.Yaji K.Asano A,et al.Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypert-ens,2007,30(12):1205-1210
[20]潘桂林.徐达华.高潮,等.脂联素：心血管疾病新的危险预测因子.心血管病学进展,2008,29(4)：628-632
[21]Yamauchi T.Nio Y.Maki T, et al.Targeted disruption of AdipoRl and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med.2007,13(8):332-339
[22]Mao X.Kikani CK.Riojas RA, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function Nat Cell Biot,2006,8(7):516-523
[23]Hattori Y.Suzuki M.Hattori S, et al. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells.Diabetologia.2003,46(5):1543-1549
[24]Chen H.Montagnani M.Funahashi T, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. JBiol Chem.2003,278(7):45021-45026
[25]Ouchi N.Kihara S.Funahasi T, et al.Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue.Circulation,2003,107(3):671-674
[26]M atsuzawa Y.Funahmshi T.Kihara S, et al. Adiponectin and metabolic syndrome.Arterioseler Thromb vase Biol,2004,24(2):29-33
[27]Esposito K.Pontillo A.Di Palo C,et al. Effect of weight loss and lifestyle changes on vascular inflammato-ry markers in obese women; arandomized trial. JAMA 2003,289:1799-804
[28]Takemura Y.Ouehi N.Shibata R,et al. Adiponectin modulates inflammatory reactions via calreticulin rec-eptor dependent clearance of early apoptotic bodies.Clin Invest,2007,117(5):375-386
[29]Berg AH.Combs TP.Du X, et al.The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med,2001,7(7):947-53
[30]Maeda N.Shimomura I.Kishida K,el al. Diet-induced insulin resistance in micelacking adiponectin/ ACRP30.Nat Med,2002,8(5):2654-2660
[31]Yamamoto Y.Hirose H.Saito I,et al. Correlation of the adipocytederived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population.Clin Sci (Lond),2002,103(4):137-42
[32]Spranger J.Kroke A.Mohlig M,et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet, 2003,361(3):226-8
[33]Julius S. Kjeldsen SE.Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial.Lancet.2004,363: 2022-2031
[34]Yilmaz MI.Sonmez A.Caglar K,et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton).2007,12(5):147-153
[35]Benson SC.Pershadsingh HA.Ho CI, et al. Identification of telmisartan as a unique angiotensin II recept-or rantagonist with selective PPAR gammamodulating activity.Hypertension,2004,43(2):993-1002
[36]Schupp M.Janke J.Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferators activated receptor-gamma activity.Circulation,2004,109(8):2054-2057
[37]Imai J.Katagiri H.Yamada T, et al. Cold exposure suppresses serum adiponectin levels through sympat-hy etic nerve activation in mice. Obesity(Silver Spring),2006,14(6):1132-1141
[38]Nowak L. Adamczak M. Wiecek A, et al. Blockade of sympathetic nervous system activity by rilm eni-dine increases plasma adiponectin concentration in patients with essential hypertension. Am JHypertens, 2005,18(4):1470-1475
[39]Kusminski CM. McTernan PG. Schraw T, et al. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum.Diabetologia,2007,50(4):634-642
[40]Adamczak M.Wiecek A.Funahashi T,et al. Decreased plasma adiponectin concentration in patients with essential hypertension.Am J Hypertens,2003,16(2):72-75
[41]Mallamaci F.Zoccali C.Cuzzola F,et al.Adiponectin in essential hypertension. Nephrol,2002,15(3):507-511
[42]Cezari M.Zanchetta M.Maiolino G,et al.Low plasma adiponectin is a hallmark of the metabolic syndr-ome in nondiabetic hypertensive high-risk patients.Hypertension,2005,46(3):823-825
[43]李新立,童敏,徐琼等.平均动脉压水平与血清脂联素浓度的相关性研究.中华心血管病杂志,2007,35(4)：320-324
[44]Baumbach GL.Heistad DD. Remodeling of cerebral arterioles in chronic hypertension.Hypertension,19-89,13(3):968-969
[45]张维忠.早期发现和检测亚临床血管病变.中华心血管病杂志,2007,35(10)：881-882
[46]Joseph T. Flynn. What is the significance of increased carotid intima media thickness in hypertensive a-dolescents?Hypertension,2006,48(2):23-24
[47]孙宁玲.血管弹性功能应作为高血压亚临床损害评估的一个重要靶点.中国循环杂志,2008,23(3)：161-163
[48]胡大一.重视踝臂指数,关注下肢外周动脉病.中国医药导刊,2005,7(1)：29
[49]Greenland P. Abrams J. Aurigemma GP, et al.Prevention Conference V:Beyond secondary prevention: Identifying the high risk patient for primary prevention:Noninvasive tests of atherosclerotic burden:wri-ting Group III.Circulation,2000,101 (1):16-22
[50]Duprea D.HOPE brings hope for the use of the ankle brachial index as cardiovascular risk marker[J]. Eur heart,2004,25(2):1-2
[51]Resnik HE. Lindsay RS. McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality:The strong Heart Study. Circulation,2004,109(5):733-739
[52]BrevettiG. PiseioneF.SilvestroA, et al. Increased inflammatory status and higher prevalence of three ves-sel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb haemost,2003,89(6):1058-1063
[53]胡大一.杨士伟.踝臂指数对冠状动脉狭窄程度的预测价值,中国医刊.2005,4(4)：46-48
[54]Me Demott MM. LiuK, et al. Ankle brachial index and subclinical cardiac and carotid disease..Aepidem lol,2005,162(1):33-41
[55]Paolo Calabro. CRP and the risk of atherosclerotic events. Semin Immunopathol,2009,31 (2):79-94
[56]Norihiko Ohashia. The impact of visceral adipose tissue and high-molecular weight adiponectin on car-dio-ankle vascular index in asymptomatic Japanese subjects. Metabolism Clinical and Experimental. 2009,3(58):1023-1029
[57]Kunihiho koshiba. Efficacy glimepiride on insulin resistance, adipocytokines, and atherosclerosis. The journal of medical investigation,2006,2(53):87-94
[2]翁心植等译.心肺血管报,1984,2(1)：21
[3]陈宏.高血压血管重构及高血压状态下的颈动脉血管重构.中国组织工程研究与临床康复,2007,2(14)：2724-2729
[4]孙宁玲.血管弹性功能应作为高血压亚临床损害评估的一个重要靶点.中国循环杂志,2008,23(3)：161-163
[5]张维忠.早期发现和检测亚临床血管病变.中华新血管病杂志,2007,35(10)：881-882
[6]Dzau VJ.Antman EM.Black HR, et al. The cardiovascular disease continuum validated :clinical eviden-ce of improved patient outcomes: Pathop-hysiology and clinical trial evidence.Circulation,2006,(114): 2850-2870
[7]CleemJL. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel detection, evaluation, and treatment of high blood cholesterol in adults(adult treatment panelⅢ).JAMA,2001,285(19):2486-2497
[8]Scherer PE. Adipose tissue:from lipid storage compartment to endocrine organ. Diabetes.2006,55 (3): 1537-1545
[9]Adamczak M. Wiecek A. Funahashi T, et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens,2003,16(2):72-75
[10]Yang WS.Lee WJ.Funahashi T,et al.Plasma adipnectin levels in overweight and obese Asians.Obes Res,2002,10(11):1104-1110
[11]Paolo Calabro. Enrica Golia,et al.CRP and the risk of atherosclerotic events. Semin Immunopathol 2009,4 (31):79-94
[12]胡大一.重视踝臂指数,关注下肢外周动脉疾病.中国医药导刊,2005,7(1)：29-31
[13]Greenland P. Abrams J. Aurigemma GP, et al.Prevention Conference V:beyond secondary prevention: identifying the high risk patient for primary prevention:noninvasive tests of atherosclerotic burden: Writing Group.Circulation,2000,101 (1):16-22
[14]Scherer PE. Willians S. Fogliano M, et al. A novel serum protein similar to Cl q, produced exclusively in adipocytes. BioChem,1995,270(10):26746-26749
[15]Nakano Y. Tobe T. Choi-Miura NH, et al. Isolation and characterization of GBP28.a novel gelatin bi-nding protein purified from human plasma. BioChem (Tokyo),1996,120(3):803-812
[16]Arita Y.Kihara S.Ouchi N,et a 1.Paradoxical decrease of an adipose-specific protein, adiponectin in obe-sity. Biochem Biophys Res Commun,1999,257(10):79-83
[17]Tsioufis C. Dimitriadis K. Antoniadid D, et al.Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Hypertens,2004, 17:470-476
[18]Schulze M. Rimm E. Shai I, et al.Relationships of between adiponectin and glycemic control, blood lipi-ds,and inflammatory makers in men with type 2 diabetes. Diabetes Care,2004,27:1680-1687
[19]毋淑珍,赵洛沙,杨文等.原发性高血压患者血清脂联素水平及与血压、胰岛素抵抗的关系.中国心血管病研究杂志,2007,6(5)：414-416
[20]Mallamaci F. Zoccali C. Culola F, et al.Adiponectin in essential hypertension.Nephrol,2002,15:507-511
[21]Wing-Sun Chow. Bernard M.Y. Cheung. Annette W.K, et al. Hypoadiponectinemia as a Predictor for the development of Hypertension,A 5-Year Prospective Study. Am j Hypertens,2007,49:1455-1461
[22]Costas Tsioufis.Kyriakos Dimitriadis.Dmitris Chatzis, et al.Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Circulation,2005,5 (5):94 6-951
[23]李新立,童敏,徐琼等.平均动脉压水平与血清脂联素浓度的相关性研究.中华心血管病杂志,2007,35(4)：320-324
[24]Zoico E.Di Francesco V.Mazzali C, et al.Adipocytokines,for distribution, and insulin resistance in eldely men an women.Gerontol A Bio Sci,2004,59(9):935-939
[25]J.S.Nam, J.S.Park, M.H.Cho, et al.The association between pulse wave velocity and metabolic syndrome and adiponectin in patients with impaired fasting glucose:cardiovascular risks and adiponectin in IFG. Diabetes research and clinical practice.2009,84(3):145-151
[26]周淑娴,雷娟,张玉玲等.高血压患者胰岛素抵抗与血清脂联素及炎症标志物水平.中华高血压杂志,2008,16(2)：166-170
[27]Anna Maria Sironi. Alessandro Pingitore. Sergio Ghione, et al. Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Am j Hypertens,2008, 51(3):282-288
[28]常彩云.血清脂联素水平与胰岛素抵抗、高血压的相关性研究：[硕士学位论文].山东：山东大学,2007
[29]Yoshio Iwashima, Tomohiro Katsuya, Kazuhiko Ishikawa, et al. Hypoadiponectinemia is an independ-ent risk factor for hypertension. Am j Hypertens,43(6):1318-1323
[30]Fasshauer M.Klein J. Neumann S, et al.Adiponectin gene expression is inhibited by beta-adrenergic sti-mulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett.,2001,507(3):142-146.
[31]Sharma AM.Janke J.Gorzelniak K,et al. Angiotensin bloekade prevents type2 diabetes by formation of fat cells.Hyertension,2002,40(5):609-611
[32]FasshauerM,KleinJ,NeumannS, et al. Adiponectin gene expression 15inhibited By beta-adrenergic stimulation via ProteinkinaseAin3T3-LladiPocytes.FEBS Lett,2001,507(2):142-146
[33]Kondo H.Shimomura I.Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes:a candidate gene for the insulin resistance syndrome. Diabetes.2002,51(8):2325-2328.
[34]Iwashima Y.Katsuya T. Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hyper- tension. Hypertension,2004,43(4):1318-1323
[35]Joseph T. What is the significance of increased carotid intima media thickness in hypertensive adolesce-nts? Hypertension,2006,48(5):23-24
[36]Litwin M.Trelewicz J. Wawer Z et al. Intima-media thickness and arterial elasticity in hypertensive ch-ildren:controlled study. Pediatr Nephrol,2004,19(1):161-114
[37]Tzou WS. Douglas PS. Srinivasan SR, et al.Increased subclinical atherosclerosis in young adults with metabolic syndrome. The Bogalusa Heart Study. J Am Coll Cardiol.2005,46:457-463
[38]Mattace-Raso F.van der Cammen T. Hofman A, et al. Arterial stiffness and risk of coronary heart dise-ase and stroke; The Rotterdam Study. Circulation,2006,113(4):657-663
[39]Ouchi N.Kihara S.Arita Y,et al.Adipocyte—derived plasma protein, adiponectin, suppresses lipid ac-cumulation and class A scavenger receptor expression in human monocyte—derived macmphages.Circ-ulation,2001,103(8):1057-1060
[40]Altinova AE. Toruner F.Bukan N, et al. Decreased plasma adiponectin is associated with insulin resista-nce and HDL cholesterol in overweight subjects. Endocr J 2007,54(5):221-226
[41]Sasaki R.Yamano S, et al. Vascular remodeling of the carotid artery in patient with untreated essential hypertension increases with age. Hypertens Res,2002,25(3):373-379
[42]Nilsson PM. Engstrom G. Hedblad B,et al. Plasma adiponectin levels in relation to carotid intima-media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol.2006,26(9):2758-2762
[43]张竹林.脂联素、血管内皮功能与代谢综合征相关性研究：[硕士学位论文].山西：山西医科大学,2007
[44]T. Hansena. A.hlstrom a, et al. Visceral adipose tissue, adiponectin levels and insulin resistance are rela-ted to atherosclerosis as assessed by whole-body magnetic resonance angiography in an elderly populat-ion.Atherosclerosis,2008,11(7):1016-1023
[45]Pilar Arnaiz. Monica Acevedo b.Salesa Barja, et al. Adiponectin levels, cardiometabolic risk factors and markers of subclinical atherosclerosis in children. Circulation,2008,8 (7):217-224
[46]Safar ME. Pulse pressure in essential hypertension:clinical and therapeutical implication. Hypertension,1989,7(5):769-776
[47]张维忠.早期发现和检测亚临床血管病变.中华心血管病杂志,2007,35(10)：881-882
[48]孙宁玲.血管弹性功能应作为高血压亚临床损害评估的一个重要靶点.中国循环杂志,2008,23(3)：161-163
[49]Kobayashi K.Akishita M.Yu W, et al.Interrelationship between no-invasive measurements of atherosc-lerosis:flow-mediated dilation of branchial artery,carotid intima-media thickness and pulse wave veloc-Ity. Atherosclerosis,2004,173(5):13-18
[50]Sikkink CJ.van Asten WN. vant Hof MA,et al. Decreased ankle/brachial index in relation to morbidi-ty and mortality in patients with peripheral arterial disease. Vasc Med,1997,2(9):169-173
[51]Hirsch AT. Haskal ZJ. Hertzer NR,等著.杨金刚.王建旗.李觉.等编译.外周动脉疾病诊疗指南[M]上海,同济大学出版社,2006,2(17)：42-45
[52]杨静.李新立.黄峻等.高血压患者血清抵抗素水平与大动脉弹性的关系.中华心血管病杂志,2009,37(3)：244-247
[53]何大渊.余静等.高血压病患者血浆Apelin-12和踝臂指数的相关影响因素.中华临床医学实践杂志,2006,12(5)：497-500
[54]Nguyen QM. Srinivasan SR. Xu JH, et al. Racial (black-white) divergence in the association between adi-ponectin and arterial stiffness in asymptomatic young adults:the Bogalusa heart study. Hypertens, 2008,21(5):553-557
[55]刘伯芹.血浆脂联素水平与冠脉病变及PWI、 ABI的关系研究：[硕士学位论文].青岛：青岛医科大学,2009
[56]Kunihiho koshiba. Efficacy glimepiride on insulin resistance, adipocytokines, and atherosclerosis. The journal of medical investigation,2006,2(53):87-94
[1]Scherer PE.Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes.2006,55(3): 1537-1545
[2]Kadowaki T.Yamauchi T.Kubota N,et al. Adiponectin and adiponectin receptors in insulin resistance, di abetes, and the metabolic syndrome. J Clin Invest.2006,116(6):1784-1792
[3]Kearney PM.Whelton M.Reynolds K,et al.Global burden of hypertension: analysis of worldwide data. L ancet.2005,365(9):217-223
[4]Funahashi T.Shimomura I.Adiponectin replenishment ameliorates obesity-related hypertension. Hyperte-nsion.2006,47(7):1108-1116
[5]Iwashima Y.Katsuya T.Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hyperte-nsion.Hypertension.2004,43(2):1318-1323
[6]Scherer PE.Willians S.Fogliano M, et al.A novel serum protein similar to Clq, produced exclusively in adipocytes.J Biol Chem,1995,270(5):2646-2649
[7]Maeda K, Okubo K, Shimomura I, et al.cDNA cloning and expression of a novel adipose specific colla-gen like factor apM1(adipose most abundant gene transcript).Biochem Biophys Res Commun,1996, 221(8):286-289
[8]Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin bind-ing protein purified from human plasma J Biochem (Tokyo),1996,120(3):803-812
[9]Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.Biochem Biophys Res Commun,1999,257(6):79-83
[10]Ohashi K. Ouchi N.Kihara S,et al.Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease.J Am Coil Cardiol.2004,43(7):1195-1200
[11]Stumvoll M.Tshritter O.Frissche A, et al.Association of the T-Gpilymorphism in adiponectin with obesit and insulin sensitivity,interaction with family history of type 2 diabetes,2002,51(1):37-41
[12]Sattar N.Watt P.Cherry L, et al.High molecular weight adiponectin is not associated with incident coron-ary heart disease in older women:a nested prospective case control study. J Clin Endocrinol Metab 2008,93(5):1846-1849
[13]Pajvani UB.Hawkins M.Combs TP, et al. Complex distribution, not absolute amount of adiponectin,corr-elates with thiazolidinedionemediated improvement in insulin sensitivity. J Biol Chem.2004,279(7):121-52-12162
[14]Tonelli J.Li W.Kishore P, et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.Diabetes.2004,53(10):1621-1629
[15]Lara-Castro C.Luo N.Wallace P, et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster.Diabetes.2006,55(5):249-259
[16]Kondo H.Shimomura L.Maukawa Y,et al.Association of adipo nectin mutation with type 2 diabetes:a ca-ndidate gene for the insulin resistance syndrome.Diabetes,2002,51(7):2325-2328
[17]Bacha F.Saad R.Gungor N, et al.Does adiponectin explmn the lower insulin sensitivity and hyperinsulin-emia of African-American children. Diabetes,2005,6(2):100-102
[18]Maeda N.Takab ashi M.Funab ashi T,et al.PPARgamma ligands increase expression and plasma concen-trateons of adiponectin,an adipose—derived protein.Diabetes,2001,50(9):2094-2099
[19]Chujo D.Yaji K.Asano A,et al.Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypert-ens,2007,30(12):1205-1210
[20]潘桂林.徐达华.高潮,等.脂联素：心血管疾病新的危险预测因子.心血管病学进展,2008,29(4)：628-632
[21]Yamauchi T.Nio Y.Maki T, et al.Targeted disruption of AdipoRl and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med.2007,13(8):332-339
[22]Mao X.Kikani CK.Riojas RA, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function Nat Cell Biot,2006,8(7):516-523
[23]Hattori Y.Suzuki M.Hattori S, et al. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells.Diabetologia.2003,46(5):1543-1549
[24]Chen H.Montagnani M.Funahashi T, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. JBiol Chem.2003,278(7):45021-45026
[25]Ouchi N.Kihara S.Funahasi T, et al.Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue.Circulation,2003,107(3):671-674
[26]M atsuzawa Y.Funahmshi T.Kihara S, et al. Adiponectin and metabolic syndrome.Arterioseler Thromb vase Biol,2004,24(2):29-33
[27]Esposito K.Pontillo A.Di Palo C,et al. Effect of weight loss and lifestyle changes on vascular inflammato-ry markers in obese women; arandomized trial. JAMA 2003,289:1799-804
[28]Takemura Y.Ouehi N.Shibata R,et al. Adiponectin modulates inflammatory reactions via calreticulin rec-eptor dependent clearance of early apoptotic bodies.Clin Invest,2007,117(5):375-386
[29]Berg AH.Combs TP.Du X, et al.The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med,2001,7(7):947-53
[30]Maeda N.Shimomura I.Kishida K,el al. Diet-induced insulin resistance in micelacking adiponectin/ ACRP30.Nat Med,2002,8(5):2654-2660
[31]Yamamoto Y.Hirose H.Saito I,et al. Correlation of the adipocytederived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population.Clin Sci (Lond),2002,103(4):137-42
[32]Spranger J.Kroke A.Mohlig M,et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet, 2003,361(3):226-8
[33]Julius S. Kjeldsen SE.Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial.Lancet.2004,363: 2022-2031
[34]Yilmaz MI.Sonmez A.Caglar K,et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton).2007,12(5):147-153
[35]Benson SC.Pershadsingh HA.Ho CI, et al. Identification of telmisartan as a unique angiotensin II recept-or rantagonist with selective PPAR gammamodulating activity.Hypertension,2004,43(2):993-1002
[36]Schupp M.Janke J.Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferators activated receptor-gamma activity.Circulation,2004,109(8):2054-2057
[37]Imai J.Katagiri H.Yamada T, et al. Cold exposure suppresses serum adiponectin levels through sympat-hy etic nerve activation in mice. Obesity(Silver Spring),2006,14(6):1132-1141
[38]Nowak L. Adamczak M. Wiecek A, et al. Blockade of sympathetic nervous system activity by rilm eni-dine increases plasma adiponectin concentration in patients with essential hypertension. Am JHypertens, 2005,18(4):1470-1475
[39]Kusminski CM. McTernan PG. Schraw T, et al. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum.Diabetologia,2007,50(4):634-642
[40]Adamczak M.Wiecek A.Funahashi T,et al. Decreased plasma adiponectin concentration in patients with essential hypertension.Am J Hypertens,2003,16(2):72-75
[41]Mallamaci F.Zoccali C.Cuzzola F,et al.Adiponectin in essential hypertension. Nephrol,2002,15(3):507-511
[42]Cezari M.Zanchetta M.Maiolino G,et al.Low plasma adiponectin is a hallmark of the metabolic syndr-ome in nondiabetic hypertensive high-risk patients.Hypertension,2005,46(3):823-825
[43]李新立,童敏,徐琼等.平均动脉压水平与血清脂联素浓度的相关性研究.中华心血管病杂志,2007,35(4)：320-324
[44]Baumbach GL.Heistad DD. Remodeling of cerebral arterioles in chronic hypertension.Hypertension,19-89,13(3):968-969
[45]张维忠.早期发现和检测亚临床血管病变.中华心血管病杂志,2007,35(10)：881-882
[46]Joseph T. Flynn. What is the significance of increased carotid intima media thickness in hypertensive a-dolescents?Hypertension,2006,48(2):23-24
[47]孙宁玲.血管弹性功能应作为高血压亚临床损害评估的一个重要靶点.中国循环杂志,2008,23(3)：161-163
[48]胡大一.重视踝臂指数,关注下肢外周动脉病.中国医药导刊,2005,7(1)：29
[49]Greenland P. Abrams J. Aurigemma GP, et al.Prevention Conference V:Beyond secondary prevention: Identifying the high risk patient for primary prevention:Noninvasive tests of atherosclerotic burden:wri-ting Group III.Circulation,2000,101 (1):16-22
[50]Duprea D.HOPE brings hope for the use of the ankle brachial index as cardiovascular risk marker[J]. Eur heart,2004,25(2):1-2
[51]Resnik HE. Lindsay RS. McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality:The strong Heart Study. Circulation,2004,109(5):733-739
[52]BrevettiG. PiseioneF.SilvestroA, et al. Increased inflammatory status and higher prevalence of three ves-sel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb haemost,2003,89(6):1058-1063
[53]胡大一.杨士伟.踝臂指数对冠状动脉狭窄程度的预测价值,中国医刊.2005,4(4)：46-48
[54]Me Demott MM. LiuK, et al. Ankle brachial index and subclinical cardiac and carotid disease..Aepidem lol,2005,162(1):33-41
[55]Paolo Calabro. CRP and the risk of atherosclerotic events. Semin Immunopathol,2009,31 (2):79-94
[56]Norihiko Ohashia. The impact of visceral adipose tissue and high-molecular weight adiponectin on car-dio-ankle vascular index in asymptomatic Japanese subjects. Metabolism Clinical and Experimental. 2009,3(58):1023-1029
[57]Kunihiho koshiba. Efficacy glimepiride on insulin resistance, adipocytokines, and atherosclerosis. The journal of medical investigation,2006,2(53):87-94